title: Replacing GnRH agonists with GnRH antagonists in oocyte recipient cycle did not adversely affect the pregnancy rates.
abstract: The synchronization of the donor stimulation with the endometrial preparation of the recipient is usually done by downregulating the recipient's pituitary with a GnRH analog.
  
  
  OBJECTIVE
  The aim of this study is to compare pregnancy and implantation rates among premenopausal oocyte recipients synchronized by pituitary suppression with GnRH agonist (Group AGO) or antagonist (Group ANTAG) and standard endometrial preparation with estrogen and gestagen.
  
  
  METHODS
  Prospective, observational, transversal, comparative study. Consecutive recipients treated at Institut Universitari Dexeus between July 2008 and December 2009.
  
  
  RESULTS
  One hundred and eighty-three premenopausal women were included. No differences were found regarding the age of donors nor the age of recipients, fertilization rates, number of embryos transferred and embryo quality. No differences were found in clinical pregnancy rates (56.1% Group AGO vs. 52.4% Group ANTAG).
  
  
  CONCLUSIONS
  The administration of GnRH antagonists during endometrial preparation in oocyte recipients facilitates synchronization without affecting the pregnancy rate.
authors: Department of Obstetrics, Gynaecology and Reproductive Medicine, Institut Universitari Dexeus, Gran Via Carles III, 71-75, 08028 Barcelona, Spain. pacmar@dexeus.com
authors: Francisca
authors: F
authors: Martínez
authors: Laura
authors: L
authors: Latre
authors: Elisabet
authors: E
authors: Clua
authors: Ignacio
authors: I
authors: Rodriguez
authors: Buenaventura
authors: B
authors: Coroleu
mesh_terms: D000328:Adult; D000736:Androstenes / Q000494:pharmacology; D010064:Embryo Implantation / Q000187:drug effects*; D004717:Endometrium / Q000187:drug effects; D004997:Ethinyl Estradiol / Q000494:pharmacology; D005260:Female; D005300:Fertility Agents, Female / Q000494:pharmacology*; D007987:Gonadotropin-Releasing Hormone / Q000819:agonists* / Q000031:analogs & derivatives / Q000037:antagonists & inhibitors / Q000494:pharmacology; D006727:Hormone Antagonists / Q000494:pharmacology*; D006785:Hospitals, University; D006801:Humans; D007247:Infertility, Female / Q000628:therapy; D008597:Menstrual Cycle / Q000187:drug effects*; D018587:Oocyte Donation; D011247:Pregnancy; D018873:Pregnancy Rate; D011372:Progestins / Q000494:pharmacology; D013030:Spain; D055815:Young Adult
chemical_list: D000736:Androstenes; D005300:Fertility Agents, Female; D006727:Hormone Antagonists; D011372:Progestins; C534342:drospirenone and ethinyl estradiol combination; D007987:Gonadotropin-Releasing Hormone; D004997:Ethinyl Estradiol; C061018:ganirelix